Continuing Medical Education (CME): Introduction to Opioid-Induced Constipation (OIC)
CME Information
TARGET AUDIENCE
This activity is targeted to any clinician with interest in education on OIC, including primary care physicians, nurse practitioners, physician assistants, emergency room physicians, and pediatricians.
RELEASE/EXPIRATION DATE
This enduring material will be available beginning December 1, 2024, through December 1, 2025.
LEARNING OBJECTIVES
After participating in this educational activity, participants should be better able to:
(1) Understand pathophysiology of OIC including key mechanisms.
(2) Recognize the clinical presentation of OIC.
(3) Review diagnostic criteria and tools for a diagnosis.
(4) Discuss pharmacologic and nonpharmacologic interventions for OIC.
METHOD OF PARTICIPATION
To receive credit for this activity, the participant must read the CME information (including learning objectives and disclosures) and participate in the entire activity. Upon finishing the activity, the participant will need to complete the session post-test, evaluation, and all required personal information. After successful completion of the activity, participant will receive their CME certificate instantly via email to submit to their appropriate licensing boards.
ACCREDITATION/DESIGNATION STATEMENTS
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AIMEC and the American Chronic Pain Association. AIMEC is accredited by the ACCME to provide continuing medical education for physicians.
AIMEC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.
Nurse Practitioners/Nurses
The American Academy of Nurse Practitioners Certification Board (AANPCB) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Other Healthcare Professionals
All other healthcare professionals will receive a certificate of participation.
UNLABELED USE DECLARATION
During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.
DISCLAIMER
The opinions, ideas, recommendations, and perspectives expressed during this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, AIMEC, advisory boards and consultants, or the activity's commercial supporters.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant provided by Salix Pharmaceuticals.
FACULTY/PLANNING COMMITTEE DISCLOSURES
All relevant financial relationships have been mitigated for this activity.
Lynn R. Webster, MD – Faculty/Content Developer
Exec VP Scientific Affairs
Dr. Vince Clinical Research
Salt Lake City, Utah
Senior Fellow
Center for U.S. Policy, Washington, DC
Chief Medical Officer
PainScripts
Dr Lynn R. Webster has relevant financial relationships with ineligible
companies to disclose:
Consultant: CognifiSense, Elysium Pharmaceuticals, Ensysce Biosciences, Quivive Pharma, Salix Pharmaceuticals, Trevi Therapeutics
Advisory Board: AdhereRx, Ensysce Biosciences, KemPharm, Medlogix
Travel Expenses: AdhereRx, Elysium Pharmaceuticals, Ensysce Biosciences, PainScript
All relevant financial relationships have been mitigated. Dr Webster does not intend to discuss the off-label use of a product.
The following individuals have no relevant financial relationships:
Scott Farmer – Content Developer/Planner
Executive Director, AIMEC
Roger Cady, MD - Independent Peer Reviewer
Consultant
Kathy Sapp - Planner
Chief Executive Officer, ACPA
This activity is accredited by AIMEC.
Acknowledgement
The information contained in these continuing medical education materials is for educational purposes only and should not be considered specific instructions for individual patients. This material is not intended to represent the best or only methods or procedures appropriate for the medical situation discussed; rather the material is intended to present an approach, view, statement or opinion of the authors, which may be helpful, or of interest to other practitioners. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind. The information contained in these materials is not intended to substitute for independent professional judgment or treatment. While AIMEC has made reasonable efforts to present accurate information in these materials, no warranty, expressed or implied, is offered. By accessing these continuing medical education materials and/or checking the “I Agree” box on the next page, the user acknowledges and understands that the AIMEC disclaims all responsibility and fault for the use and application of the information contained in these materials and for adverse effects resulting directly or indirectly from the use of these materials, from undetected errors, or from the user’s misunderstanding of the materials. Furthermore, the user acknowledges and understands that the user waives any claim for fault he/she has, or may have in the future, against AIMEC, and all of its subsidiaries, affiliates, partners, contractors, vendors, officers, employees, agents, insurers, representatives, successors, and/or assigns, for injury or other damage that may result in any way from the use of these materials, whether arising in contract, tort, or otherwise. By checking the box on the next page, I acknowledge that I have carefully read and fully understand all provisions in the disclaimer above, and freely and knowingly agree to the disclaimer as written.
TARGET AUDIENCE
This activity is targeted to any clinician with interest in education on OIC, including primary care physicians, nurse practitioners, physician assistants, emergency room physicians, and pediatricians.
RELEASE/EXPIRATION DATE
This enduring material will be available beginning December 1, 2024, through December 1, 2025.
LEARNING OBJECTIVES
After participating in this educational activity, participants should be better able to:
(1) Understand pathophysiology of OIC including key mechanisms.
(2) Recognize the clinical presentation of OIC.
(3) Review diagnostic criteria and tools for a diagnosis.
(4) Discuss pharmacologic and nonpharmacologic interventions for OIC.
METHOD OF PARTICIPATION
To receive credit for this activity, the participant must read the CME information (including learning objectives and disclosures) and participate in the entire activity. Upon finishing the activity, the participant will need to complete the session post-test, evaluation, and all required personal information. After successful completion of the activity, participant will receive their CME certificate instantly via email to submit to their appropriate licensing boards.
ACCREDITATION/DESIGNATION STATEMENTS
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AIMEC and the American Chronic Pain Association. AIMEC is accredited by the ACCME to provide continuing medical education for physicians.
AIMEC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.
Nurse Practitioners/Nurses
The American Academy of Nurse Practitioners Certification Board (AANPCB) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Other Healthcare Professionals
All other healthcare professionals will receive a certificate of participation.
UNLABELED USE DECLARATION
During their presentation, faculty may discuss unlabeled or investigational use which is not approved for a commercial product. Faculty members are required to disclose this information to the audience when referring to an unlabeled or investigational use.
DISCLAIMER
The opinions, ideas, recommendations, and perspectives expressed during this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, AIMEC, advisory boards and consultants, or the activity's commercial supporters.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant provided by Salix Pharmaceuticals.
FACULTY/PLANNING COMMITTEE DISCLOSURES
All relevant financial relationships have been mitigated for this activity.
Lynn R. Webster, MD – Faculty/Content Developer
Exec VP Scientific Affairs
Dr. Vince Clinical Research
Salt Lake City, Utah
Senior Fellow
Center for U.S. Policy, Washington, DC
Chief Medical Officer
PainScripts
Dr Lynn R. Webster has relevant financial relationships with ineligible
companies to disclose:
Consultant: CognifiSense, Elysium Pharmaceuticals, Ensysce Biosciences, Quivive Pharma, Salix Pharmaceuticals, Trevi Therapeutics
Advisory Board: AdhereRx, Ensysce Biosciences, KemPharm, Medlogix
Travel Expenses: AdhereRx, Elysium Pharmaceuticals, Ensysce Biosciences, PainScript
All relevant financial relationships have been mitigated. Dr Webster does not intend to discuss the off-label use of a product.
The following individuals have no relevant financial relationships:
Scott Farmer – Content Developer/Planner
Executive Director, AIMEC
Roger Cady, MD - Independent Peer Reviewer
Consultant
Kathy Sapp - Planner
Chief Executive Officer, ACPA
This activity is accredited by AIMEC.
Acknowledgement
The information contained in these continuing medical education materials is for educational purposes only and should not be considered specific instructions for individual patients. This material is not intended to represent the best or only methods or procedures appropriate for the medical situation discussed; rather the material is intended to present an approach, view, statement or opinion of the authors, which may be helpful, or of interest to other practitioners. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind. The information contained in these materials is not intended to substitute for independent professional judgment or treatment. While AIMEC has made reasonable efforts to present accurate information in these materials, no warranty, expressed or implied, is offered. By accessing these continuing medical education materials and/or checking the “I Agree” box on the next page, the user acknowledges and understands that the AIMEC disclaims all responsibility and fault for the use and application of the information contained in these materials and for adverse effects resulting directly or indirectly from the use of these materials, from undetected errors, or from the user’s misunderstanding of the materials. Furthermore, the user acknowledges and understands that the user waives any claim for fault he/she has, or may have in the future, against AIMEC, and all of its subsidiaries, affiliates, partners, contractors, vendors, officers, employees, agents, insurers, representatives, successors, and/or assigns, for injury or other damage that may result in any way from the use of these materials, whether arising in contract, tort, or otherwise. By checking the box on the next page, I acknowledge that I have carefully read and fully understand all provisions in the disclaimer above, and freely and knowingly agree to the disclaimer as written.